Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, presented data showing that patients with amyotrophic lateral sclerosis given edaravone intravenously in 10 to 14 day cycles for 48 weeks experienced significantly less functional loss as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented at the 27th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neuron disease) in Dublin.